News | EP Lab | December 03, 2020

Esophageal Cooling May Help Prevent Injury From Cardiac Ablations

Atrial fibrillation ablations can cause esophageal injury, but an FDA-cleared temperature management system may help protect the esophagus

Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus similar to a standard gastric tube and connected to an external heat exchange unit, creating a closed-loop system for heat transfer to increase or decrease patient temperature. Its placement in the esophagus, with proximity to blood flow from the heart and great vessels, allows highly efficient heat transfer. EPs are now looking at the device as a way to prevent RF damage to the esophagus during ablations.

Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus similar to a standard gastric tube and connected to an external heat exchange unit, creating a closed-loop system for heat transfer to increase or decrease patient temperature. EPs are now looking at the device as a way to prevent RF damage to the esophagus during cardiac ablations.
 

December 3, 2020 – Attune Medical reports the first major peer-reviewed clinical publication using its ensoETM device in cardiac ablation procedures to see if using the esophageal space for temperature management could decrease collateral thermal injury from electrophysiology (EP) radiofrequency (RF) ablation for atrial fibrillation (AF).

The IMPACT Study was published Nov. 17, 2020 in the journal EP Europace.[1] It details the work by Dr. Mark Gallagher and colleagues. Gallagher is a cardiologist at St. George’s University Hospital, London, U.K. The team evaluated the use of the ensoETM for AF ablation protection of the esophagus. Catheter ablation occurs at a thin walled part of the heart that is against the esophagus. The RF energy can go through the myocardium and damage the underlying tissue nest to the heart. 

Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus (similar to a standard orogastric tube) and connected to an external heat exchange unit, creating a closed-loop system for heat transfer to increase or decrease patient temperature. Its placement in the esophagus, with proximity to blood flow from the heart and great vessels, allows highly efficient heat transfer. Unlike surface warming devices, ensoETM‘s internal placement does not impede patient access during surgery and allows gastric decompression and administration of fluids and medications.

Another study, OPERA, was also published recently in Europace by different authors that showed intraesophageal temperature monitoring during cardiac ablation procedures using a traditional temperature sensor probe did not affect the incidence of endoscopically detected esophageal lesions.[2] This highlights the need for continued research regarding alternative methods to protect the esophagus from thermal injury during cardiac ablations.

The company also completed the final closing of a $4 million convertible note offering. The funds will be used to increase the company’s commercial and clinical presence while supporting further studies in key device application areas.  
 
“As uses of esophageal-based temperature management continue to expand, we are committed to supporting clinical studies such as the IMPACT trial to advance clinical practice in growing fields such as cardiac ablation” commented Keith Warner, CEO. “Our mission is to apply temperature management solutions using our proprietary esophageal-based device to maximize clinical benefit across a range of applications and patient groups”

Attune Medical developed the ensoETM medical device technology to simplify access to the patient’s core to efficiently control temperature and is the only device FDA-cleared for use in the esophagus for whole-body temperature management. The ensoETM device is used in critical care units, operating rooms, and emergency departments for the intentional modulation of patient core temperature and can be rapidly placed by most trained healthcare professionals.

For more information: www.ensoetm.com

References:

1. Lisa W M Leung, Abhay Bajpai, Zia Zuberi, Mark M Gallagher, et al. Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study. EP Europace, euaa276. Published online 17 November 2020. https://doi.org/10.1093/europace/euaa276.

2. Katharina Schoene, Arash Arya, Friederike Grashoff, et al. Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial. EP Europace, Volume 22, Issue 10, October 2020, Pages 1487–1494, https://doi.org/10.1093/europace/euaa209.

 

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve